Konan Yvette N, Gurny Robert, Allémann Eric
School of Pharmacy, University of Geneva, 30, quai Ernest Ansermet, CH-1211 Geneva 4 , Switzerland.
Int J Pharm. 2002 Feb 21;233(1-2):239-52. doi: 10.1016/s0378-5173(01)00944-9.
The feasibility of producing sterile and freeze-dried polyester nanoparticles was investigated. Various poly(D,L-lactide-co-glycolide) and poly(D,L-lactide) were selected as biodegradable polymers. Using the salting-out procedure, process parameters were optimized to obtain sub-200 nm particles. After purification, the nanoparticle suspensions containing different lyoprotectants were sterilized by filtration. Freeze-drying was performed using vials covered with 0.22 microm membrane filters in order to preserve the suspensions from bacterial contamination. Sterility was assessed on the final product according to pharmacopoeial requirements using the membrane filtration method. With all polymers tested, sub-200 nm particles could be obtained. Nanoparticles with a size as low as 102 nm were prepared with good reproducibility and narrow size distribution. Upon freeze-drying, it appeared that complete redispersion of all types of polyester nanoparticles could be obtained in presence of the lyoprotectants tested such as saccharides while aggregation was observed without lyoprotectant. Sterility testing showed no microbial contamination indicating that sterile nanoparticulate formulations have been achieved.
研究了生产无菌冻干聚酯纳米颗粒的可行性。选择了各种聚(D,L-丙交酯-共-乙交酯)和聚(D,L-丙交酯)作为可生物降解聚合物。采用盐析法优化工艺参数以获得直径小于200 nm的颗粒。纯化后,含有不同冻干保护剂的纳米颗粒悬浮液通过过滤进行灭菌。使用覆盖有0.22微米膜过滤器的小瓶进行冷冻干燥,以防止悬浮液受到细菌污染。根据药典要求,使用膜过滤法对最终产品进行无菌性评估。对于所有测试的聚合物,均可获得直径小于200 nm的颗粒。制备出了尺寸低至102 nm的纳米颗粒,具有良好的重现性和窄尺寸分布。冷冻干燥后,在测试的冻干保护剂(如糖类)存在下,所有类型的聚酯纳米颗粒似乎都能完全重新分散,而在没有冻干保护剂的情况下则观察到聚集现象。无菌测试表明没有微生物污染,这表明已实现了无菌纳米颗粒制剂。